retatrutide clinical trials south africa SA doctors caution against use of unauthorised weight-loss drug A Study of Retatrutide (LY3437943)

Eli Lilly initiated the TRIUMPH Phase 3 program in late 2024 , with interim data expected to support a 2027 FDA submission and peak GLP-1 market sales projections of USD 12 to USD 18 billion

GLP-1 primarily reduces appetite and slows gastric emptying, GIP enhances fat metabolism and insulin sensitivity, and glucagon increases energy expenditure and fat oxidation

refrigerate on arrival

There is a deeper-than-usual trough followed by a recovery period as the next dose begins rebuilding levels

Lifestyle changes promoting a reduction in caloric intake and an increase in energy expenditure represent the first-line action [4]